Kiniksa Pharmaceuticals International, plc (KNSA)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Product Revenue, Net	840.85M	677.56M	417.03M
License and Collaboration Revenue	-	-	6.21M
Revenue (Total)	840.85M	677.56M	423.24M

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
United States Revenue	839.83M	676.75M	421.43M
United Kingdom Revenue	1.02M	814.00K	930.00K
Rest of World Revenue	-	-	875.00K
Revenue (Total)	840.85M	677.56M	423.24M

Data Source: Fiscal.ai Last updated: Jul 28, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 20, 2026

Data Sources Report a data error